Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.